Flatiron Health and Foundation Medicine Unveil Powerful Oncology Information Resource to Advance Precision Medicine

NEW YORK & CAMBRIDGE, Mass.–(BUSINESS WIRE)– Flatiron
Health and Foundation
Medicine, Inc. (NASDAQ:FMI) today announced the launch of a
clinico-genomic database designed to help researchers and
biopharmaceutical partners accelerate the development of targeted
therapeutics and immunotherapies to treat cancer. The clinico-genomic
database, containing information on nearly 20,000 patients, is one of
the largest and most comprehensive information efforts of its kind in
oncology. The HIPAA-compliant database integrates rich genomic profiling
data from patients whose tumors were sequenced with Foundation
Medicine’s comprehensive genomic profiling (CGP) assays with annotated
longitudinal clinical and outcomes data developed by Flatiron from
electronic health records (EHR). By making clinico-genomic data
available as part of the clinical research process, researchers will
have access to real-world information in designing the next generation
of oncology therapeutics and clinical trials, ultimately paving the way
for new and more precise therapies for cancer patients.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161103005263/en/

“We are incredibly excited to introduce in partnership with Foundation
Medicine this clinico-genomic database,” said Amy Abernethy, M.D.,
Ph.D., chief medical and chief scientific officer, Flatiron Health.
“This collaboration enables us to help researchers and life science
companies use real-world evidence inclusive of detailed genomic
information, patient and disease clinical characteristics, treatments
received, and patient-level outcomes like disease progression, tumor
response and mortality to identify patient populations with unmet needs
and expedite plans for drug development and clinical trials.”

The clinico-genomic database includes de-identified linked clinical and
genomic data from patients across a variety of tumor types allowing for
a continuously updated, longitudinal view of a patient’s clinical,
diagnostic and therapeutic journey. The database combines anonymized,
HIPAA-compliant, research-grade patient data, including diagnosis,
treatment and clinical outcomes captured through Flatiron’s EHR data
collection platform. This data is matched with deep, highly validated
molecular information, including genomic findings, variant
interpretations and bio-informatic data, generated by FoundationOne^®,
FoundationOne^® Heme and FoundationACT™.

“Foundation Medicine and Flatiron together are uniquely positioned to
accomplish what many others in oncology are trying to achieve, namely,
delivering a highly validated lens into rich longitudinal
clinico-genomic data and analysis to advance therapeutic development,”
said Steven Kafka, Ph.D., president and chief operating officer,
Foundation Medicine. “We look forward to working with our biopharma
collaborators to leverage this unique data set to help advance and
accelerate the development of precision therapeutics.”

Expected to grow in the coming months, the clinico-genomic database is
the first of several products that Foundation Medicine and Flatiron plan
to co-develop using a comprehensive, HIPAA-compliant information
platform. The two companies are exploring partnerships within the
broader research and academic communities to accelerate utilization of
this clinico-genomic database for novel drug development and clinical
trial applications.

ABOUT FLATIRON HEALTH

Flatiron Health is a healthcare technology company harnessing the power
of real-world data to accelerate research and improve cancer care. The
company works with healthcare providers, life sciences organizations and
academic centers to collect, aggregate and analyze data for over 1.5
million active cancer patients. Today, over 250 cancer clinics and 10 of
the top 12 life science companies are using Flatiron’s platforms.
Flatiron is backed by Google Ventures, First Round Capital, Roche and
others. For more information, please visit http://flatiron.com
or follow Flatiron on Twitter (@flatironhealth).

Flatiron Health^® is a registered trademark
of Flatiron Health, Inc.

ABOUT FOUNDATION MEDICINE

Foundation Medicine (NASDAQ:FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient’s unique cancer. The company offers a full suite of
comprehensive genomic profiling assays to identify the molecular
alterations in a patient’s cancer and match them with relevant targeted
therapies, immunotherapies and clinical trials. Foundation Medicine’s
molecular information platform aims to improve day-to-day care for
patients by serving the needs of clinicians, academic researchers and
drug developers to help advance the science of molecular medicine in
cancer. For more information, please visit http://www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine^®, FoundationOne^®
and FoundationOne^® Heme are registered
trademarks and FoundationACT™ is a trademark of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements for Foundation
Medicine This press release contains “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
implementation of the collaboration between Foundation Medicine and
Flatiron, the ability Foundation Medicine and Flatiron to grow the
database, the utility of the clinico-genomic database, and the ability
of the clinico-genomic database to effectively support the research
requirements of researchers and biopharmaceutical companies involved in
drug development and clinical trials. All such forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These
risks and uncertainties include the risks that the collaboration is not
implemented or is not implemented as quickly or as fully as anticipated;
Flatiron is not able to gain access to sufficient amounts of clinical
information and Foundation Medicine is not able to generate sufficient
amounts of genomic data to create a robust and successful product; the
clinico-genomic database does not perform as expected or is not widely
adopted or used by researchers; the clinico-genomic database is not
financially sustainable; and the risks described under the caption “Risk
Factors” in Foundation Medicine’s Annual Report on Form 10-K for the
year ended December 31, 2015, which is on file with the Securities and
Exchange Commission, as well as other risks detailed in Foundation
Medicine’s subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the
date of the release, and Foundation Medicine and Flatiron undertake no
duty to update this information unless required by law.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005263/en/